Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Panax notoginseng saponins enhance osteogenesis-angiogenesis coupling to ameliorate osteoporosis combined with intervertebral disc degeneration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Fangli, Hu Hao, Chen Yan, Guo Wei, Liu Rixu, Chen Shuai, Yujia Shi, Xu Shun, Zheng Shicong, Chen Yushu, Zhang Kaiwei, Zhang Zijian, Zou Xuenong, Lin Sixiong, Qian Dongyang
Аннотация
BACKGROUND: Osteoporosis (OP) combined with Intervertebral disc degeneration (IDD) is a chronic degenerative disease. There are no drugs that simultaneously treat both IDD and OP. Panax notoginseng saponins (PNS) can treat OP or ameliorate IDD, respectively, indicating its potential for simultaneous treatment of both conditions. The specific biological mechanism by which PNS treats OP combined with IDD and the key bioactive compounds involved require further investigation.
METHODS: The effects of oral administration of PNS on OP and IDD were evaluated in mice using micro-CT scanning and immunofluorescence. In vitro experiments involved the preparation of PNS serum for cell culture, performing tube formation assays on HUVECs, RNA sequencing followed by KEGG, GO, and DEGs analysis, as well as Western blotting. Furthermore, HPLC-MS analysis and molecular docking were conducted to identify key bioactive biomolecules in PNS serum.
RESULTS: The animal model confirmed that the OP condition can exacerbate IDD and that PNS treatment simultaneously treats OP combined with IDD. Additionally, PNS promotes the coupling of osteogenesis and angiogenesis in the lumbar vertebrae. Moreover, PNS serum enhances the tube formation ability of HUVECs and promotes the expression of angiogenesis-related genes in bEnd.3 cells, increases the expression of Slit3 in BMSCs and lumbar vertebrae, promoting the phosphorylation of the ERK signalling pathway. Finally, through HPLC-MS analysis and molecular docking predictions, the key bioactive molecule NG-R4 was identified in PNS serum.
CONCLUSION: PNS enhances the ERK phosphorylation in BMSCs through its metabolic component NG-R4, stimulating Slit3 secretion to promote the coupling of osteogenesis and angiogenesis.
METHODS: The effects of oral administration of PNS on OP and IDD were evaluated in mice using micro-CT scanning and immunofluorescence. In vitro experiments involved the preparation of PNS serum for cell culture, performing tube formation assays on HUVECs, RNA sequencing followed by KEGG, GO, and DEGs analysis, as well as Western blotting. Furthermore, HPLC-MS analysis and molecular docking were conducted to identify key bioactive biomolecules in PNS serum.
RESULTS: The animal model confirmed that the OP condition can exacerbate IDD and that PNS treatment simultaneously treats OP combined with IDD. Additionally, PNS promotes the coupling of osteogenesis and angiogenesis in the lumbar vertebrae. Moreover, PNS serum enhances the tube formation ability of HUVECs and promotes the expression of angiogenesis-related genes in bEnd.3 cells, increases the expression of Slit3 in BMSCs and lumbar vertebrae, promoting the phosphorylation of the ERK signalling pathway. Finally, through HPLC-MS analysis and molecular docking predictions, the key bioactive molecule NG-R4 was identified in PNS serum.
CONCLUSION: PNS enhances the ERK phosphorylation in BMSCs through its metabolic component NG-R4, stimulating Slit3 secretion to promote the coupling of osteogenesis and angiogenesis.